Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Hajishengallis George) > Compstatin :

Compstatin : a C3-targeted complement inhibitor reaching its prime for bedside intervention

Mastellos, Dimitrios C. (author)

Yancopoulou, Despina (author)

Kokkinos, Petros (author)

Huber-Lang, Markus (author)

Hajishengallis, George (author)

Biglarnia, Alireza (author): Uppsala universitet,Transplantationskirurgi

Lupu, Florea (author)

Nilsson, Bo (author): Uppsala universitet,Klinisk immunologi

Risitano, Antonio M. (author)

Ricklin, Daniel (author)

Lambris, John D. (author)

show less...

(creator_code:org_t)

2015-03-09
2015
English.
In: European Journal of Clinical Investigation. - : Wiley. - 0014-2972 .- 1365-2362. ; 45:4, s. 423-440

Related links:: https://europepmc.or...; show more...; https://urn.kb.se/re...; https://doi.org/10.1...; show less...

Research review (peer-reviewed)

Abstract Subject headings

There is a growing awareness that complement plays an integral role in human physiology and disease, transcending its traditional perception as an accessory system for pathogen clearance and opsonic cell killing. As the list of pathologies linked to dysregulated complement activation grows longer, it has become clear that targeted modulation of this innate immune system opens new windows of therapeutic opportunity for anti-inflammatory drug design. Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement-based inhibitors. Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering with convertase formation and C3 cleavage. As the convergence point of all activation pathways and a molecular hub for crosstalk with multiple pathogenic pathways, C3 represents an attractive target for therapeutic modulation of the complement cascade. A multidisciplinary drug optimization effort encompassing rational wet' and in silico synthetic approaches and an array of biophysical, structural and analytical tools has culminated in an impressive structure-function refinement of compstatin, yielding a series of analogues that show promise for a wide spectrum of clinical applications. These new derivatives have improved inhibitory potency and pharmacokinetic profiles and show efficacy in clinically relevant primate models of disease. This review provides an up-to-date survey of the drug design effort placed on the compstatin family of C3 inhibitors, highlighting the most promising drug candidates. It also discusses translational challenges in complement drug discovery and peptide drug development and reviews concerns related to systemic C3 interception.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP -- Annan medicin och hälsovetenskap -- Övrig annan medicin och hälsovetenskap (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Other Medical and Health Sciences -- Other Medical and Health Sciences not elsewhere specified (hsv//eng)

Keyword

clinical translation
complement-based drug design
compstatin
Cp40
nonhuman primate models
peptidic C3 inhibitors

Publication and Content Type

ref (subject category)
for (subject category)

Find in a library

European Journal of Clinical Investigation (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Mastellos, Dimit ...; Yancopoulou, Des ...; Kokkinos, Petros; Huber-Lang, Mark ...; Hajishengallis, ...; Biglarnia, Alire ...; show more...; Lupu, Florea; Nilsson, Bo; Risitano, Antoni ...; Ricklin, Daniel; Lambris, John D.; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Other Medical an ...; and Other Medical an ...

Articles in the publication: European Journal ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se